F3Y.F Microba Life Sciences Limited

Healthcare Diagnostics & Research Frankfurt Exchange
0.0175 EUR
Close of Nov 12, 2026
0.0165 0.0525
Market cap
EUR 13.0M
P/E
-
P/B
0.86x
ROE
-85.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is F3Y.F undervalued?

Graham number

The Graham number of Microba Life Sciences Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Microba Life Sciences Limited fundamental analysis

No fundamental analysis for Microba Life Sciences Limited yet.

Microba Life Sciences Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Microba Life Sciences Limited

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for path…

Full company profile